Novavax COVID‑19 Shots Green‑lit for Singapore Adults
Health Sciences Authority gives the thumbs‑up
On Monday, January 14, the Health Sciences Authority (HSA) announced that Novavax’s Covid‑19 vaccine is now officially approved for anyone aged 18 and up.
The move follows an interim authorisation granted on 3 Feb 2022 under the Pandemic Special Access Route (PSAR). The first shipment is slated to arrive in the next few months, so you’ll soon be able to book a slot.
What’s the buzz about the vaccine?
- Two 5‑microgram doses—the plan is to jabcred two doses 3 weeks apart.
- HSA says it meets quality, safety and efficacy standards, and the benefits beat the risks.
- Experts from the Medicines Advisory Committee and the Panel of Infectious Diseases backs the decision.
Protein‑based vs. mRNA: The difference in a nutshell
Unlike the Pfizer–BioNTech and Moderna mRNA shots that tell your cells to produce a sneaky viral protein, the Novavax vaccine hands your immune system a real, harmless piece of the virus. It’s a “protein sub‑unit” approach—think piece of cake rather than the whole cake.
When your body recognises this protein, it gets ready to fight the spike protein that the coronavirus uses to sneak into your cells. It’s a smart three‑step plan: show, warn, & defend.
In short, you’re not getting any copy‑and‑paste genetic instructions from Wuhan—just a well‑prepared immune army.
Quick takeaway
Novavax is the new kid on the block, a protein‑based game‑changer for adults in Singapore. With approval in hand and vaccine stocks on the way, it’s time to pencil in your shots and keep the virus at bay.
